Inmune Bio Inc. 8-K Report: Key Insights on Major Events (Feb 10, 2025)

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

1. Entity Information:

• Name: Inmune Bio Inc.
• CIK Number: 0001711754
• SEC File Number: 001-38793
• EIN: 47-5205835
• Address: 225 NE Mizner Blvd. Suite 640, Boca Raton, FL 33432
• Phone Number: 858-964-3720

2. Filing Type:

• Form Type: 8-K, which is used to report major events that shareholders should know about.

3. Filing Date:

• Date of Report: February 10, 2025.

4. Stock Information:

• Security Type: Common Stock
• Par Value: $0.001 per share
• Ticker Symbol: INMB
• Exchange: NASDAQ

5. Context and Units:

• The report is structured with a context defined for the date of February 10, 2025, indicating that the information reported is as of this date.
• The report utilizes various units of measure, including USD for monetary values and shares for equity.

Insights:

• The report is part of a regulatory requirement for Inmune Bio Inc., indicating that there may have been significant events or changes that warranted immediate disclosure.
• The presence of the form type (8-K) suggests that investors and stakeholders should pay attention to the details contained within, as it may impact stock performance or corporate strategy.
• Given the company's listing on NASDAQ, it is important for investors to monitor this filing for any material changes that could affect share price.

Overall, this 8-K filing serves as an important communication tool between Inmune Bio Inc. and its shareholders, providing necessary transparency regarding corporate events and financial standing as of February 10, 2025.